• Molecular NameMidazolam
  • SynonymDea No; 2884; Midazolam Base; Midazolam Hcl; Midazolamum [INN-Latin]
  • Weight325.774
  • Drugbank_IDDB00683
  • ACS_NO59467-70-8
  • Show 2D model
  • LogP (experiment)3.27
  • LogP (predicted, AB/LogP v2.0)2.98
  • pka6.2
  • LogD (pH=7, predicted)2.93
  • Solubility (experiment)40.0 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.98
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds1
  • TPSA29.66
  • StatusFDA approved
  • AdministrationOral, I.M., I.V., parenteral
  • PharmacologyAn ultra short-acting benzodiazepine derivative. It has potent anxiolytic, amnestic, hypnotic, anticonvulsant, skeletal muscle relaxant, and sedative properties.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability44.0
  • Protein binding98.0
  • Volume of distribution (VD)1.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMidazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam, and 4-hydroxymidazolam.
  • Half life2.2~6.8 h
  • ExcretionRenal
  • Urinary Excretion<1
  • Clerance6.6 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)LD50=825 mg/kg
  • LD50 (mouse)N/A